Aim: The aim of the study was to evaluate the usefulness of CA125 measurements in
ovarian cancer diagnostics in pre-versus postmenopausal women. Material and methods …

Objective To investigate the possible role of α-fetoprotein (AFP), carcinoembryonic antigen
(CEA), and CA-125 in the ovarian follicle. Design α-Fetoprotein, CEA, and CA-125 were …

The CA-125-antigen could not only be identified in the epithelium of serous ovarian
carcinoma, but also in the regular surface epithelium of the endometrium, the decidua and …

Single serum samples were obtained during the first trimester of pregnancies with a
retrospectively normal outcome (n= 150), ectopic pregnancies (n= 38) and anembryonic …

Purposes To identify patients with highly elevated serum CA-125 levels and analyze their
clinical characteristics. Methods Patients with non-malignant gynecologic disease (NMGDs …

The tumor marker CA 125 was initially thought to be specific for ovarian malignancies.
Subsequently it was found to be raised in a variety of benign conditions, including …

Background: CA 125 is a tumor-associated antigen. Its high levels are usually associated
with ovarian malignancies, whereas smaller increases in the levels were associated with …

No noninvasive diagnostic tests reliably discriminate endometriosis and other pelvic pain-
causing diseases. CA-125, originally introduced as a marker for ovarian cancer, is increased …

Aim Our aim was to confirm that preoperative CA 125 serum level can be useful for
discrimination between benign and malignant masses in the pelvis. Methods Preoperative …

The original CA 125 serum tumor marker test is a homologous double-determinant (OC 125
monoclonal antibody based) assay for the quantification of tumor associated mucin-like CA …